Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director · President & CEO | April 16, 2026 | April 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ultragenyx Pharmaceutical Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 735,739 |
Reported balance
After 2026-04-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 76,745 · Balance 735,739 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.52 · Expires 2036-04-16 | Direct | 132,693 |
Reported balance
After 2026-04-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-16 · Grant · Acquired 132,693 · Balance 132,693 F4: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. |
| Common StockSEC Table I · non-derivative | IndirectBy Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200909 | 1,758,985 |
Reported balance
Holding disclosure · report date 2026-04-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,758,985 F3: Amount of securities beneficially owned following reported transaction reflects the contribution of an aggregate of 400,000 shares previously owned indirectly by the reporting person to two grantor retained annuity trusts (each, a "GRAT"). |
| Common StockSEC Table I · non-derivative | IndirectBy GRAT | 200,000 |
Reported balance
Holding disclosure · report date 2026-04-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 200,000 |
| Common StockSEC Table I · non-derivative | IndirectBy GRAT | 200,000 |
Reported balance
Holding disclosure · report date 2026-04-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 200,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F3: Amount of securities beneficially owned following reported transaction reflects the contribution of an aggregate of 400,000 shares previously owned indirectly by the reporting person to two grantor retained annuity trusts (each, a "GRAT").
F4: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2026 Filed Apr 20, 2026 21:19 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 132,693 | $0.00 Strike: $24.52 | $0.00 |
DisclosureSEC source: 0001193125-26-164308 · ownership.xml · derivative · entry 5 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,693 Underlying: Common Stock · 132,693 shares Expires 2036-04-16 F4 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:19 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 76,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164308 · ownership.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735,739 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 00:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 54,404 | $22.80 | $1,240,411.20 |
DisclosureSEC source: 0001193125-26-089278 · ownership.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 658,994 F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range F4 · balance_after: Includes 490 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025. F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 00:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 71,177 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-089278 · ownership.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 712,908 F1 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 73,434 | $42.10 | $3,091,571.40 |
DisclosureSEC source: 0000950170-25-032779 · ownership.xml · nonDerivative · entry 3 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 641,731 F3 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 78,448 | $0.00 Strike: $42.92 | $0.00 |
DisclosureSEC source: 0000950170-25-032779 · ownership.xml · derivative · entry 5 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,448 Underlying: Common Stock · 78,448 shares Expires 2035-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 107,292 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032779 · ownership.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 715,165 F2 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 43,268 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032779 · ownership.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 607,873 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 25,000 | $42.48 | $1,062,000.00 |
DisclosureSEC source: 0000950170-25-032779 · ownership.xml · nonDerivative · entry 4 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 Disclosed balance after: 2,158,985 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.89 to $42.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 30, 2024 Filed Dec 31, 2024 19:05 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 11,727 | $42.23 | $495,231.21 |
DisclosureSEC source: 0000950170-24-141485 · ownership.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 Disclosed balance after: 2,183,985 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.58 to $43.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 23:44 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 8,273 | $50.00 | $413,650.00 |
DisclosureSEC source: 0000950170-24-135521 · ownership.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 Disclosed balance after: 2,195,712 Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 23:44 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-135521 · ownership.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 Disclosed balance after: 2,203,985 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 15:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 20,000 | $55.85 | $1,117,000.00 |
DisclosureSEC source: 0000950170-24-103811 · ownership.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · See FN Disclosed balance after: 2,223,985 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.02 to $57.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 Read SEC document |
| August 06, 2024 Filed Aug 7, 2024 18:48 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 20,000 | $50.17 | $1,003,400.00 |
DisclosureSEC source: 0000950170-24-092608 · ownership.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · See FN Disclosed balance after: 2,243,985 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 70,094 | $0.00 Strike: $53.69 | $0.00 |
DisclosureSEC source: 0000950170-24-026625 · ownership.xml · derivative · entry 5 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,094 Underlying: Common Stock · 70,094 shares Expires 2034-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,132 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026625 · ownership.xml · nonDerivative · entry 3 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 563,913 F3 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 17,417 | $53.69 | $935,118.73 |
DisclosureSEC source: 0000950170-24-026625 · ownership.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 560,781 F2 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 38,428 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026625 · ownership.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 578,198 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 20:49 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 30,000 | $45.00 | $1,350,000.00 |
DisclosureSEC source: 0001209191-24-002989 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 539,770 F1 · shares: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.69 to $45.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| December 29, 2023 Filed Jan 2, 2024 21:07 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 30,000 | $47.87 | $1,436,100.00 |
DisclosureSEC source: 0001209191-24-000071 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 569,770 F1 · shares: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.54 to $48.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 27 shares acquired under the Company's Amended and Restated 2014 Employee Stock Purchase Plan on October 31, 2023. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| October 19, 2023 Filed Oct 23, 2023 21:14 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 47,853 | $0.00 Strike: $6.86 | $0.00 |
DisclosureSEC source: 0001209191-23-053351 · doc4.xml · derivative · entry 4 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,853 shares Expires 2023-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares thereafter such that the option fully vested on the fourth anniversary of the grant date. Read SEC document |
| October 19, 2023 Filed Oct 23, 2023 21:14 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 47,853 | $33.52 | $1,604,032.56 |
DisclosureSEC source: 0001209191-23-053351 · doc4.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 599,743 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.57 to $34.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 567 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| October 19, 2023 Filed Oct 23, 2023 21:14 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 47,853 | $6.86 | $328,271.58 |
DisclosureSEC source: 0001209191-23-053351 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 647,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:52 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 83,500 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-23-016041 · doc4.xml · derivative · entry 5 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,500 Underlying: Common Stock · 83,500 shares Expires 2033-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:52 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 16,140 | $45.65 | $736,791.00 |
DisclosureSEC source: 0001209191-23-016041 · doc4.xml · nonDerivative · entry 3 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 599,176 F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F5 · balance_after: Reflects transfer of directly owned shares of common stock from the Reporting Person to a trust indirectly held by the Reporting Person that have taken place since the most recent prior report on Form 4. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:52 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 46,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016041 · doc4.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,606 F2 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:52 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 8,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016041 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 569,406 F1 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 21:45 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 19,582 | $45.57 | $892,351.74 |
DisclosureSEC source: 0001209191-23-000276 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,108 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.94 to $46.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 92,360 | $0.00 Strike: $67.37 | $0.00 |
DisclosureSEC source: 0001209191-22-015799 · doc4.xml · derivative · entry 4 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,360 Underlying: Common Stock · 92,360 shares Expires 2032-03-01 F4 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 52,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015799 · doc4.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634,226 F2 · shares: Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 12,162 | $67.37 | $819,353.94 |
DisclosureSEC source: 0001209191-22-015799 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 582,185 F1 · kind: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). Read SEC document |
| December 10, 2021 Filed Feb 1, 2022 18:41 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005839 · doc5.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200 Disclosed balance after: 2,209,741 Read SEC document |
| October 14, 2021 Filed Oct 18, 2021 22:44 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 853 | $81.00 | $69,093.00 |
DisclosureSEC source: 0001209191-21-060749 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,347 F1 · kind: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 06, 2021 Filed May 10, 2021 22:11 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 852 | $115.71 | $98,584.92 |
DisclosureSEC source: 0001209191-21-031383 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,200 F1 · kind: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 03, 2021 Filed May 5, 2021 15:32 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 30,000 | $107.80 | $3,234,000.00 |
DisclosureSEC source: 0001209191-21-030211 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200 Disclosed balance after: 2,259,741 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.14 to $110.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $142.47 | $0.00 |
DisclosureSEC source: 0001209191-21-017537 · doc4.xml · derivative · entry 5 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2031-03-01 F7 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 30,000 | $141.80 | $4,254,000.00 |
DisclosureSEC source: 0001209191-21-017537 · doc4.xml · nonDerivative · entry 4 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 Disclosed balance after: 2,289,741 F5 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.89 to $143.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 16,342 | $142.47 | $2,328,244.74 |
DisclosureSEC source: 0001209191-21-017537 · doc4.xml · nonDerivative · entry 3 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,052 F3 · kind: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 15,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017537 · doc4.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 612,394 F2 · shares: Represents 5,099 shares of common stock and 10,354 RSUs into which previously granted performance stock units were converted on March 1, 2021 upon certification of the performance metric. The RSUs will fully vest on March 1, 2022. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017537 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,941 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 23:45 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 30,000 | $136.90 | $4,107,000.00 |
DisclosureSEC source: 0001209191-21-001583 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 Disclosed balance after: 2,329,741 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.66 to $138.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 27, 2020 Filed Feb 4, 2021 01:03 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GiftCommon Stock | 31,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007554 · doc5.xml · nonDerivative · entry 4 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,941 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| November 19, 2020 Filed Feb 4, 2021 01:03 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007554 · doc5.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 Disclosed balance after: 2,349,741 Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:44 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 30,000 | $96.82 | $2,904,600.00 |
DisclosureSEC source: 0001209191-20-056859 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 Disclosed balance after: 2,359,741 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $100.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 23:23 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 852 | $92.69 | $78,971.88 |
DisclosureSEC source: 0001209191-20-055182 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,189 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · ownership.direct: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 20:26 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 30,000 | $82.63 | $2,478,900.00 |
DisclosureSEC source: 0001209191-20-049130 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 Disclosed balance after: 2,389,741 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.51 to $85.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 17:22 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 40,000 | $85.35 | $3,414,000.00 |
DisclosureSEC source: 0001209191-20-042479 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 Disclosed balance after: 2,419,741 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.74 to $87.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 18:17 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 1,334 | $69.38 | $92,552.92 |
DisclosureSEC source: 0001209191-20-033883 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 611,041 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: The amount set forth in column 5 reflects dispositions from gifts that will be reported in a Form 5 within 45 days after the Issuer's fiscal year end. Read SEC document |
| May 27, 2020 Filed Feb 4, 2021 01:03 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GiftCommon Stock | 40,422 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007554 · doc5.xml · nonDerivative · entry 3 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,941 Read SEC document |
| May 22, 2020 Filed Feb 4, 2021 01:03 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007554 · doc5.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 Disclosed balance after: 2,349,741 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.